Overview of tigecycline efficacy and safety in the treatment of complicated skin and structure infections - A European perspective

Journal of Chemotherapy

Volumn 20, Issue SUPPL. 1, 2008, Pages 20-27

  Teras, Juri ^a   Gardovskis, J ^b   Vaasna, T ^c   Kupcs, U ^d   Pupelis, G ^e   Dartois, N ^f   Jouve, S ^g   Cooper, A ^f  

^a North Estonian Regional Hospital   (Estonia)

^b PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^c TARTU UNIVERSITY CLINICS   (Estonia)

^d Valmeira Hospital   (Latvia)

^e Clinical Hospital Gailezers   (Latvia)

^f PFIZER INC   (United States)

^g Neuroscience Department   (France)

Author keywords

Clinical Trials.gov identifier: NCT00228410; Complicated skin and skin structure infections; Randomized study; Tigecycline

Indexed keywords

AZTREONAM; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; FURUNCULOSIS; HUMAN; INFECTION COMPLICATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; SKIN INFECTION;

EID: 57749119267     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.supplement-1.20     Document Type: Article

References (39)

1. Wilson SE. Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative Gram-positive infections. Surg Infect (Larchmt) 2001; 2: 25-35.
2. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-419.
3. Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002; 43: 303-309.
4. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-430.
5. Nichols R. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44 (suppl A): 19-23.
6. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179-1181.
7. Diekema D, Pfaller M, Schmitz F, Smayevsky J, Bell J, Jones R, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region of the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32: S114-S132.
8. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006 355, 666-674.
9. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-567.
10. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-332.
11. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52: 173-179.
12. Fluit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-1638.
13. Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004; 48: 323-325.
14. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-487.
15. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
16. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard.), 5th ed. NCCLS document. M11-A15. National Committee for Clinical Laboratory Standards, Wayne, PA, 2001.
17. Methods for dilution antimicrobial susceptibility tests for microbes that grow aerobically; approved standard), 6th ed. National Committee for Clinical Laboratory Standards, Wayne, PA, 2003.
18. Performance standards for antimicrobial disk susceptibility tests; approved standard.), 8th ed. National Committee for Clinical Laboratory Standards, Wayne, PA, 2003.
19. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-229.
20. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. In Abstracts of the 42nd Interscience Conference Antimicrobial Agents and Chemotherapy 2002: Abstract A1403.
21. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. In Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy 2003: Abstract L739.
22. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, 200 Group. A multicenter, randomized, open-label safety and efficacy study of tigecycline dosages for complicated skin and skin structure infections in hospitalized patients. Clin Therapeut 2004; 26: 704-714.
23. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41, Suppl 5: S341-353.
24. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41, Suppl 5: S354-367.
25. National Cancer Institute. Common Terminology Criteria for Adverse Events. 2006 V3 http://ctep.cancer.gov/forms/CT-CAEv3.pdf Accessed on: 10 March 2007.
26. Nord CE, Sillerstrom E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006; 50: 3375-3380.
27. Wilcox MH, Freeman J. Analysis of reports of Clostridium difficile infection in phase 2 and 3 studies of tigecycline In Abstracts of the European Conference on Clinical Microbiology and Infectious Diseases, Munich, Germany, 2007; Poster 1683.
28. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-1065.
29. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875-1881.
30. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003; 185: 369-375.
31. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-1078.
32. Fejfarova V, Jirkovska A, Skibova J, Petkov V. [Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome]. Vnitr Lek 2002; 48: 302-306.
33. Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern Med J 2005; 35, Suppl 2: S97-105.
34. Gordon SM. Antibiotic prophylaxis against postoperative wound infections. Cleve Clin J Med 2006; 73, Suppl 1: S42-45.
35. Elston DM. Community-acquired methicillin-resistant Staphylococcus aureus. J Am Acad Dermatol 2007; 56: 1-16; quiz 17-20.
36. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-174.
37. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-122.
38. Greiner W, Rasch A, Kohler D, Salzberger B, Fatkenheuer G, Leidig M. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. Clin Microbiol Infect 2007; 13: 264-268.
39. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611-614.